Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.
Kastritis E, Kostopoulos IV, Terpos E, Paiva B, Fotiou D, Gavriatopoulou M, Kanellias N, Ziogas DC, Roussou M, Migkou M, Eleutherakis-Papaiakovou E, Trougakos IP, Tsitsilonis O, Dimopoulos MA.
Kastritis E, et al.
Blood Cancer J. 2018 May 24;8(5):46. doi: 10.1038/s41408-018-0086-3.
Blood Cancer J. 2018.
PMID: 29795385
Free PMC article.
No abstract available.